Clinical trials: Acromegaly
Acromegaly
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00658879
- Testing
- Somavert (Pegvisomant)
- Volunteers
- 251 people
- Sponsor
- Pfizer
Acromegaly
Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
To assess the safety and effectiveness of Somatuline® Depot (lanreotide) Injection when administered by a health care professional (HCP), the patient, the patient's partner or parent/guardian as part of their routine acromegaly…
- Trial name
- SODA (NCT00686348)
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Ipsen